Recent Advancements in Organotin(IV) Complexes as Potent Cytotoxic Agents

Author:

Devi Jai1,Boora Ankit1,Rani Manju1,Arora Tanisha1

Affiliation:

1. Department of Chemistry, Guru Jambheshwar University of Science and Technology, Hisar-125001, Haryana, India

Abstract

Background: Cancer cases have escalated by approximately 12% since1900 and incidence rate has increased faster for females than males. Cisplatin’s discovery in 1965 paved the way for the metal-based compounds as cancer therapeutics. Unfortunately, cisplatin and other platinum-based medicines causes severe side effects. Therefore, non–platinum metal complexes have been developed as alternative chemotherapy for cancer. Among non-platinum metal complexes, organotin’s are the most effective candidates in oncology due to their wide range of anticancer activity with relatively minimal toxicities towards healthy cells, better excretion from body and fewer side-effects than platinum drugs. Methods: Using DOI searching, advances made by organotin(IV) complexes coordinated with Sn–O, Sn–N and Sn–S as anticancer chemotherapeutic agents since 2018 have been summarized in this article. Chemical structure, in vitro antiproliferative activity in terms of IC50/EC50/LD50 are cumulated. Results: As reflected in this perspective, organotin(IV) complexes are found to induce high cell death via apoptosis and also several complexes demonstrated anticancer activity even higher than standard drugs. Conclusion: Undoubtedly, the organotin(IV) complexes could bring hope to morbidity and mortality of human being caused by fast spreading cancer in the whole world and can play an important role in drug discovery.

Funder

CSIR-HRDG, New Delhi

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Pharmacology,Molecular Medicine

Reference137 articles.

1. Ferlay J.; Ervik M.; Lam F.; Colombet M.; Mery L.; Piñeros M.; Global Cancer Observatory: Cancer Today; Inter-national Agency for Research on Cancer: Lyon. J Can Therp [https://gco.iarc.fr/today2020,12(1)

2. Deswal Y.; Asija S.; Kumar D.; Jindal D.K.; Chandan G.; Panwar V.; Kumar N.; Transition metal complexes of tria-zole-based bioactive ligands: Synthesis, spectral characteriza-tion, antimicrobial, anticancer and molecular docking studies. Res Chem Intermed 2021,48,1-27

3. Johnstone T.C.; Park G.Y.; Lippard S.J.; Understanding and improving platinum anticancer drugs--phenanthriplatin. Anticancer Res 2014,34(1),471-476

4. Löscher W.; Potschka H.; Sisodiya S.M.; Vezzani A.; Drug resistance in epilepsy: Clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev 2020,72(3),606-638

5. Ott I.; Gust R.; Non platinum metal complexes as anti-cancer drugs. Arch Pharm (Weinheim) 2007,340(3),117-126

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3